Compounding • GLP-1 • Advertising • Pharmacy Litigation

Magistrate Recommends Liability Over Compounded GLP-1 Marketing

A Florida federal magistrate judge recommended that Novo Nordisk prevail on liability against MD Exam over advertising for compounded semaglutide. The November 13 report addresses use of the Ozempic and Wegovy marks, including “oral Ozempic” and a “Wegovy Program.” The recommendation leaves remedies for further proceedings. For pharmacies and telehealth partners, the case offers a concrete reason to review how marketing identifies a compounded product and describes its relationship to an FDA-approved medicine.

By Toby C. “Chad” Frost • November 18, 2026
1 min read

In Novo Nordisk A/S v. MD Exam LLC, a Southern District of Florida magistrate judge recommended summary judgment on liability for all five claims on November 13. The claims cover trademark infringement, false advertising, and related unfair-competition theories. This is a report and recommendation for district-judge review.1

The report addresses advertising for compounded semaglutide using the Ozempic and Wegovy marks, including “oral Ozempic” and a “Wegovy Program.” The magistrate concluded that the record established misleading product descriptions and likely consumer confusion. MD Exam opposed the motion but did not properly respond to Novo’s statement of material facts, so properly supported facts were deemed admitted.2

The report recommends further proceedings on remedies. It does not award profits, corrective-advertising costs, or a defined injunction. Its reasoning concerns the challenged advertising and does not establish that all compounded semaglutide is unlawful.3

Chad’s analysis: Review the claims a patient sees before reaching the dispensing pharmacy, including a telehealth partner’s advertisements. Product names and descriptions should accurately identify what the patient will receive and avoid suggesting an unverified manufacturer affiliation or approval.

Status checked November 18, 2026: No later adopting order was located in the public sources reviewed. The complete current docket was unavailable.4

Source notes

  1. Report and Recommendation on Plaintiffs’ Motion for Summary Judgment at 1–5, 19, Novo Nordisk A/S v. MD Exam LLC, No. 1:24-cv-22064-DPG/DSW (S.D. Fla. Nov. 13, 2026), ECF No. 63.
  2. Report and Recommendation on Plaintiffs’ Motion for Summary Judgment at 1 n.2, 2–3, 7–11, 14–15, Novo Nordisk A/S v. MD Exam LLC, No. 1:24-cv-22064-DPG/DSW (S.D. Fla. Nov. 13, 2026), ECF No. 63.
  3. Report and Recommendation on Plaintiffs’ Motion for Summary Judgment at 18–19, Novo Nordisk A/S v. MD Exam LLC, No. 1:24-cv-22064-DPG/DSW (S.D. Fla. Nov. 13, 2026), ECF No. 63.
  4. U.S. Gov’t Publ’g Off., Novo Nordisk A/S v. MD Exam LLC, No. 1:24-cv-22064, Document in Context (listing Nov. 13, 2026 report and recommendation) (last visited Nov. 18, 2026).